F-star Therapeutics, Inc.
BioSniper Score
4-factor signal
Market Cap
—
Cash Runway
7.2 mo
Lead Asset
fs118 (Phase 2)
Next Catalyst
—
F-star Therapeutics, Inc.: 4 pipeline candidates · Updated within the last hour.
Go deeper on F-star Therapeutics, Inc. with Spotter
Ask follow-up questions and run a full multi-agent deep dive on FSTX — live, with citations.
Score breakdown4-factor signal · derived from public data
7.2 months
D/E 0.47 · 0% dilution
Lead: Phase 2
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Key Financialsas of September 30, 2022
Cash
$35.6M
Quarterly Burn
$16.5M
Revenue
$1.1M
Free Cash Flow
-$16.5M
Total Liabilities
$26.8M
Shareholders Equity
$56.9M
Current Ratio
3.38
Commercialization & Governance
Commercialization
- Status
- Clinical-stage
- Has Revenue
- No
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
What is F-star Therapeutics, Inc.'s lead drug candidate?
F-star Therapeutics, Inc.'s most advanced tracked candidate is fs118 (Phase 2) for PD-1/PD-L1 acquired resistance head and neck cancer, CPI-naïve non-small cell lung cancer (NSCLC), and diffuse large B-cell lymphoma (DLBCL).
Who is the CEO of F-star Therapeutics, Inc.?
Eliot Forster is the chief executive officer of F-star Therapeutics, Inc. (FSTX).
What therapeutic areas does F-star Therapeutics, Inc. focus on?
F-star Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on F-star Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.